Search clinical trials for: Relapsed or refractory, BRAFV600 or RAS-mutated solid tumors

Total 215562 results

Pierre Fabre Medicament

Recruiting

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (TavieSkin)

Metastatic Melanoma | Melanoma (Skin) | BRAF V600 Mutation

Portugal
Pfizer

Terminated

An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)

Brain Metastases

United States, Belgium, Australia, Argentina, Italy
Grupo Español Multidisciplinar de Melanoma

Completed

Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma (BRAFV600)

Stage IV Skin Melanoma

Spain
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Advanced BRAFV600 Wild-type Melanoma

United States, Korea, Republic of, Australia, Belgium, France, Russian Federation, Italy, Netherlands, Spain, United Kingdom, Brazil, Poland, Germany, Greece, Hungary
University of Utah

Withdrawn

Radiation Use During Vemurafenib Treatment

Stage IV Melanoma | BRAFV600 Mutation

United States
Pfizer

Terminated

LGX818 for Patients With BRAFV600 Mutated Tumors (SIGNATURE)

Solid Tumor | Hematologic Malignancies

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.

Withdrawn

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Melanoma

United States
UNICANCER
Merck Sharp & Dohme LLC; Pierre Fabre Medicament; European Association of Dermato...

Recruiting

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB)

Brain Metastases | Malignant Melanoma | BRAF V600 Mutation

France
University of Heidelberg Medical Center
German Cancer Research Center; University Hospital Heidelberg; Array BioPharma; Coordinating Centre for Clinical Trials Heidelberg

Active, not recruiting

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) (GMMG-BIRMA)

Relapsed or Refractory Multiple Myeloma | Patients With BRAFV600 E or BRAFV600K Mutation

Germany
CCTU- Cancer Theme
Pierre Fabre Medicament

Not yet recruiting

Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM)

Melanoma | Cancer

United Kingdom
Cambridge University Hospitals NHS Foundation Trust
University of Oxford; National Institute for Health Research, United Kingdom; Oxford University Hospitals NHS Trust

Completed

Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma (INTERIM)

Melanoma

United Kingdom
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Melanoma

United States
Melanoma Research Foundation Breakthrough Consortium
Genentech, Inc.

Terminated

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Melanoma | Metastatic Melanoma

United States
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Metastatic Melanoma

France, Italy, Spain, Brazil, Latvia, Germany, Hungary, Switzerland
Hoffmann-La Roche

Withdrawn

A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Malignant Melanoma, Neoplasms
Array BioPharma

Completed

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Metastatic Colorectal Cancer

United States, Australia, Belgium, Canada, France, Israel, Italy, Netherlands, Singapore, Spain
Hoffmann-La Roche

Completed

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Malignant Melanoma, Neoplasms

Russian Federation, Korea, Republic of, Israel, South Africa, Belarus
National Cancer Institute (NCI)

Active, not recruiting

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma

United States, Canada, Puerto Rico, Australia, New Zealand
Hoffmann-La Roche

Terminated

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Malignant Melanoma

United States, France, Australia, United Kingdom, Italy, Spain, Germany, Israel, Poland, Slovakia
Pfizer

Active, not recruiting

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Spain, Netherlands, Korea, Republic of, Italy
Genentech, Inc.

Completed

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Malignant Melanoma

United States
Celgene

Terminated

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Neoplasm Metastasis

United States, Australia
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Recurrent Melanoma | Stage IV Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Grupo Español Multidisciplinar de Melanoma
Roche Farma, S.A; Pivotal S.L.

Completed

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

Spain
GlaxoSmithKline
Pfizer

Completed

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Cancer

United States
Universitair Ziekenhuis Brussel

Completed

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT)

Stage IV Melanoma | Stage III Melanoma

Belgium
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Melanoma

United States, Korea, Republic of, United Kingdom, Australia, France, Belgium, Italy, Portugal, Spain, Brazil, Canada, Russian Federation, Germany, New Zealand, Israel, Poland, Greece, Austria, Hungary, Netherlands
Intergruppo Melanoma Italiano

Active, not recruiting

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

BRAF V600 Mutation | Melanoma Metastatic

Italy
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Spain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Belgium, Spain, Germany, Netherlands, Finland
Fondazione Melanoma Onlus

Withdrawn

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Melanoma

Italy
Hoffmann-La Roche

Completed

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Malignant Melanoma, Neoplasms

Korea, Republic of, Brazil, United States, Canada, Cyprus
Zhejiang University

Not yet recruiting

A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Metastatic Tumor
Peking University

Recruiting

UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors

Conditions or Focus of Study: B7-H3 Positive Relapsed/Advanced Malignant Solid Tumor

China
Lantern Pharma Inc.

Recruiting

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

Advanced Solid Tumor | Relapsed or Refractory Lymphomas

United States
ImmunoGenesis

Recruiting

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

Solid Tumor

United States
M.D. Anderson Cancer Center

Recruiting

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Refractory Solid Tumors

United States
Qurgen Inc.

Recruiting

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor

United States
Shanghai Yunying Medical Technology
The PLA Navy Anqing Hospital

Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Non Small Cell Lung Cancer | Liver Cancer | Bronchial Cancer

China
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Clear Cell Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Cervical Carcinoma | Malignant Pleural Mesothelioma | Esophageal Carcinoma

United States
Tarapeutics Science Inc.

Recruiting

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Advanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

China
Chinese PLA General Hospital
Zhejiang University

Recruiting

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Lymphoma | Solid Tumor, Adult | EphA2 Overexpression | TP53 R273H | TP53 R175H | TP53 R248Q | TP53 R249S

China
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL845 in Adults With Solid Tumors

Melanoma | Colorectal Cancer | Non-small Cell Lung Cancer

United States
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Advanced Solid Tumors | Relapsed Or Refractory Non-Hodgkin Lymphoma

China
ModernaTX, Inc.

Recruiting

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Australia, Spain
Novartis Pharmaceuticals
Innovative Therapies For Children with Cancer Consortium

Recruiting

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Neuroblastoma

Germany, Italy, Singapore, Spain, United States, Australia, France
Sorrento Therapeutics, Inc.

Not yet recruiting

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

Sarcoma | Cancer | Solid Tumor | Cancer of Pancreas | Hepatic Metastasis
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Lymphoma | HCC | NSCLC | Advanced Solid Tumor

China
National Cancer Institute (NCI)

Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Australia, Canada

Search clinical trials for: Relapsed or refractory, BRAFV600 or RAS-mutated solid tumors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations